CX3CL1 and neoplasm: In this study, we assessed the secretion of CX3CL1 from MTX-treated murine fibrosarcoma MC205 and melanoma B16-F10 cells undergoing immunogenic apoptosis (i.e., apoptotic cell death exhibiting ICD characteristics (10, 45)), and explored its potential as a mediator of anti-tumour immunity during ICD.